Virginia Tech Intellectual Properties, Inc.

Other

University of California

US Government As Represented by the Secretary of the Army

Stephen M Boyle

Gerhardt G Schurig

Lynette B Corbeil

Ramesh Vemulapalli

Nammalwar Sriranganathan

Silvio Cravero

Nammalwar Srirnaganathan

Richard Lloyd Warren

Mikeljon Nikolich

Luther E Lindler

David Hoover

Hamzeh Al Qublan

Ted L Hadfield

Sriranganathan Nammalwar

Garrett Smith

Aloka B Bandara

John R McOulston

Provided herein is a multivalentvaccine expressing at least one heterologousantigen. The vaccines described herein serve as an environmentally safe bivalent vaccine for protection againstandinfections simultaneously. In particular, a multivalent vaccine comprising astrain transformed with a vector that expresses at least oneantigen, where theantigen(s) is codon optimized for thestrain is provided. In some aspects, thestrain isstrain RB51 leuB and theantigen is one or more of Ag85B, Rv2660c, and ESAT6.

Multivalentvaccine for protection against mycobacterial infections and methods of using the same

A recombinant, attenuated strain oforwith a deficiency in carboxyl-terminal protease activity or tail-specific protease activity can be used as a vaccine for the prevention or treatment of Brucellosis. Prior exposure to thespecies is identified by detecting a genetic sequence for carboxyl-terminal (i.e. tail-specific) protease activity in a biological sample.

Development of a live, attenuated, recombinant vaccine for Brucellosis

This invention relates to an over-expressing homologous antigen vaccine, a method of producing the same, and use of the vaccine for prophylaxis or treatment of vertebrates at risk of or suffering from disease caused by a pathogenic micro-organism. The vaccine is an attenuated or avirulent pathogenic micro-organism that over-expresses at least one homologous antigen encoded by at least one gene derived from the pathogenic micro-organism, and may also express a heterologous antigen.

Over-expressing homologous antigen vaccine and a method of making the same

Live Brucella vaccines and methods for preparing the live vaccines protective against brucellosis are described. The vaccines are prepared by introducing a deletion in the rfbU gene of a strain of Brucella which results in attenuation of the strain while retaining the desired immunogenicity to initiate a protective immunogenic response. Other strains with varying levels of attenuation are described.

Live vaccine against Brucellosis

Over-expressing homologous antigen vaccine and a method of making the

Growing community of inventors

Blacksburg, VA, United States of America

Stephen M Boyle